Cellectar Biosciences Inc  

(Public, NASDAQ:CLRB)   Watch this stock  
Find more results for Simon Pedder�
3.10
+0.01 (0.32%)
Real-time:   10:05AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.10 - 3.30
52 week 3.00 - 9.20
Open 3.16
Vol / Avg. 1,500.00/21,348.00
Mkt cap 22.67M
P/E     -
Div/yield     -
EPS -3.59
Shares 2.87M
Beta 0.11
Inst. own 12%
Aug 20, 2014
Cellectar Biosciences Inc Earnings Call
Aug 20, 2014
Q2 2014 Cellectar Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -120.13% -117.88%
Return on average equity - -181.86%
Employees 24 -
CDP Score - -

Address

3301 Agriculture Drive
MADISON, WI 53716
United States - Map
+1-617-2441616 (Phone)
+1-608-4418121 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc. is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, its compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. The Company�s portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents. The Company's I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. Its I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Its CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Chad J. Kolean Chief Financial Officer, Vice President - Finance, Treasurer
Bio & Compensation  - Reuters
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
Bio & Compensation  - Reuters
J. Patrick Genn Vice President - Business Development
Age: 56
Bio & Compensation  - Reuters
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Paul L. Berns Independent Director
Age: 47
Bio & Compensation  - Reuters
John P. Neis Independent Director
Age: 57
Bio & Compensation  - Reuters